Bitcoin Adoption News: Top Win Rebrands, Steak N Shake Accepts BTC, Galaxy's Nasdaq Debut
Galaxy Digital (GLXY) just debuted on the Nasdaq, but it appears the financial services company's listing will be jostling for the attention of the crypto sphere's hive mind.
Crypto X — still widely known as Crypto Twitter (CT) despite the platform's name change — was abuzz with users sharing news of fast food company Steak n' Shake starting to accept bitcoin BTC payments over the Lightning network, having announced its plans to do so a week ago.
A video posted on the social-media platform shows a customer completing an order at a self-service machine, choosing the "Pay With Bitcoin" option and scanning the QR code with their Lightning wallet in the Zeus app.
Another company raising the bitcoin flag is Top Win International (TOPW), a luxury watch wholesaler, which said it will change its name to AsiaStrategy and manage its treasury in digital assets. It is, in effect, following the model of Michael Saylor's software company Strategy (MSTR), which now owns 568,840 BTC, more than 2.5% of all the bitcoin that will ever exist.
Hong Kong-based Top Win is partnering with crypto-backed venture capital firm Sora for its new pivot. Shares of the company rose as much as 45% before losing the gains to trade down 31% at $5.14.
Sora previously worked with Tokyo-based Metaplanet (3350), another company copying the Strategy model.
Galaxy, the Toronto-based crypto-focused financial services firm led by Mike Novogratz, has commenced trading on Nasdaq Global Select Market.
Novogratz, who described the listing as a "pivotal moment" for Galaxy in a letter shared via email, rang the opening bell on the Nasdaq floor on Friday.
Galaxy announced its plans at the end of last month, in which it also said GLXY would remain listed on the Toronto Stock Exchange (TSX) "for a period of time following [its] intended listing on Nasdaq."
GLXY shares traded at around $22.61 in early trading, 3.2% higher on the day. The Toronto-traded shares rose 2.98% to C$31.48 ($22.53).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Jim Cramer and Wall Street Are Watching DraftKings Inc. (DKNG)
We recently published a list of . In this article, we are going to take a look at where DraftKings Inc. (NASDAQ:DKNG) stands against other stocks on Jim Cramer and Wall Street's radar. During the May 2 episode, Cramer mentioned DraftKings Inc. (NASDAQ:DKNG) and said: 'Will DraftKings make a comeback here? We like this company very much, but the stock does seem stalled, doesn't it? Maybe it needs more states to legalize sports betting.' A woman at a betting table paying out customers who won their sports bets. DraftKings Inc. (NASDAQ:DKNG) is a digital gaming company that focuses on online sports betting, daily fantasy sports, online casino games, and a digital collectibles marketplace. Additionally, the company develops software for sports betting and iGaming across both online and retail platforms. On May 30, Morgan Stanley analyst Stephen Grambling reduced the price target on DraftKings (NASDAQ:DKNG) from 53 to $51 while maintaining an Overweight rating. The firm slightly increased estimates for its Gaming & Lodging coverage due to stronger first-quarter results, expected guidance, and updated valuations based on higher multiples. The analyst noted that low valuations in the sector indicate the market remains cautious in the near term. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
38 minutes ago
- Yahoo
China robotaxis, Indian pharma among hedge fund top picks at Sohn Hong Kong
By Summer Zhen HONG KONG (Reuters) -Hedge funds revealed their top investment ideas, ranging from Chinese self-driving taxis, an Indian drug retailer, to a Korean nuclear plant builder, at the annual Sohn investment conference in Hong Kong. This year's picks are geographically more diverse compared to last year, suggesting that investors are actively seeking to spread their exposure to counter tariff uncertainties and market volatility. San Francisco-based Flight Deck Capital sees upside potential in Chinese search engine giant Baidu, betting on its fast-growing auto-driving business. Similar to Google's self-driving unit Waymo, Baidu's Apollo Go "is the only robo-taxi player in China that's not dependent on the capital markets to scale," Flight Deck founder and managing partner Jay Kahn said at the conference on Friday. He expects China's taxi and ride-share industry to grow to around $237 billion by 2034, with Apollo taking a 15% market share. But that segment, together with Baidu's cloud business, is currently given zero valuation by the market, he said. Notably, investor optimism on Chinese firms going overseas has not been derailed by the escalating U.S.-China trade war. Hong Kong's Apeiron Capital pitched Chinese ride-hailing company DiDi Global, citing its improving margin at home and its quick market share building in Latin America. Meanwhile Triata Capital is upbeat on Chinese discount e-commerce player PDD, the owner of Temu. "One statistic that a lot of people don't know is that their MAU right now is bigger than Amazon," Triata CIO Sean Ho said, referring to Temu's monthly active users. INDIA Two investors set their sights on India's healthcare space. Singapore's Arisaig Partners favors MedPlus Health Services, a leading pharmacy chain in India, as its private label products strengthen its low-price proposition, widening the gap with competitors. "Inflation is lower, government is focusing on the middle class and consumer spending is coming off a low base. I simply believe this is the time when the consumer space in general will do better," Vatsal Mody, partner and head of India research at Arisaig Partners said in an interview ahead of the conference. India-based hedge fund startup Panvira Management is bullish on Piramal Pharma, a contract development and manufacturing organisation (CDMO), expecting its growth to accelerate to high teens and to benefit from tax rate normalisation. SECURITY AND ACTIVISTS Other emerging hedge funds focused on opportunities in the security sector driven by geopolitical conflicts. Jon Jhun, who manages Management's new Korea-focused fund, chose Hyundai Engineering & Construction, which engages in nuclear plant engineering, procurement and construction (EPC). "Korea dominates the ex-Russia, ex-China nuclear supply chain," he said. Hong Kong's Frontline Global Management picked Spanish defence firm Indra Sistemas, believing the firm will win more European contracts. On the activist investor side, UK hedge fund Palliser Capital disclosed a 3% stake in Japan's Toyo Tire at the event, urging the tire maker to boost shareholder returns by setting a "best-in-class" performance target and releasing its excess capital of about $900 million to shareholders. Seth Fischer's Oasis Management is long Japanese entertainment complex chain Round One, betting it will gain a re-rating as it ventures into the restaurant industry aiming to bring Michelin-quality Japanese food to the U.S. Sign in to access your portfolio
Business Insider
41 minutes ago
- Business Insider
AstraZeneca announces results from MATTERHORN Phase III trial of IMFINZI
Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca's (AZN) IMFINZI in combination with standard-of-care FLOT chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival, EFS, versus chemotherapy alone. Patients were treated with neoadjuvant IMFINZI in combination with chemotherapy before surgery, followed by adjuvant IMFINZI in combination with chemotherapy, then IMFINZI monotherapy. The trial evaluated this regimen versus perioperative chemotherapy alone for patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction, GEJ, cancers. In a planned interim analysis, patients treated with the IMFINZI-based perioperative regimen showed a 29% reduction in the risk of disease progression, recurrence or death versus chemotherapy alone. Estimated median EFS was not yet reached for the IMFINZI arm versus 32.8 months for the comparator arm. For the secondary endpoint of overall survival, a strong trend was observed in favor of the IMFINZI-based perioperative regimen. The trial will continue to follow OS, which will be formally assessed at the final analysis. Confident Investing Starts Here:
